Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920575'
s FCF Margin % Range Over the Past 10 Years
Min: -187474.42 Med: -33038.8 Max: -210.36
Current: -7839.53
During the past 13 years, the highest FCF Margin % of Beijing Health Guard Biotechnology was -210.36%. The lowest was -187474.42%. And the median was -33038.80%.
BJSE:920575's FCF Margin % is ranked worse than 93.1% of 956
companies
in the Biotechnology industry
Industry Median: -80.565
vs BJSE:920575: -7839.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Health Guard Biotechnology FCF Margin % Chart
BJSE:920575 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Beijing Health Guard Biotechnology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Health Guard Biotechnology FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Health Guard Biotechnology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Health Guard Biotechnology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Health Guard Biotechnology (BJSE:920575) has a FCF Margin % of -4,720.25% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beijing Health Guard Biotechnology and its competitors. According to the industry distribution chart, Beijing Health Guard Biotechnology ranks #890 out of 956 companies in the Biotechnology industry, placing it in the top 93.1%.
Is Beijing Health Guard Biotechnology's FCF Margin % too high?
Beijing Health Guard Biotechnology's current FCF Margin % is -4,720.25%. Based on the distribution chart, Beijing Health Guard Biotechnology ranks #890 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Health Guard Biotechnology has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Health Guard Biotechnology's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Health Guard Biotechnology ranks #890 out of 956 companies for FCF Margin %. This places Beijing Health Guard Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beijing Health Guard Biotechnology and its competitors. Beijing Health Guard Biotechnology's current FCF Margin % is -4,720.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Health Guard Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Beijing Health Guard Biotechnology (BJSE:920575) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.92, compared to a current price of ¥5.59 — trading 29.4% below its estimated fair value. The current FCF Margin % is -4,720.25%. Beijing Health Guard Biotechnology's overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Beijing Health Guard Biotechnology (BJSE:920575), the current FCF Margin % is -4,720.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Health Guard Biotechnology (BJSE:920575) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Health Guard Biotechnology stock appears to be undervalued.
The current stock price of ¥5.59 is trading 29.4% below its estimated GF Value™ of ¥7.92.
GuruFocus considers Beijing Health Guard Biotechnology to be Modestly Undervalued.
Key valuation signals for BJSE:920575:
FCF Margin %: -4,720.25%
GF Value™: ¥7.92 vs. price of ¥5.59 (29.4% below fair value)
No single metric tells the full story. See the BJSE:920575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Health Guard Biotechnology Inc engages in the research, development, and industrialization of recombinant protein vaccines. It mainly develops HPV vaccines in China and also advances multiple innovative candidate vaccines for other infectious diseases. Its core pipeline product includes a trivalent and a nonavalent HPV vaccine.
47GF Score
Get the complete analysis for BJSE:920575
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920575 has been successfully added to your 
